Literature DB >> 1911847

Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes.

R V Ward1, S J Atkinson, P M Slocombe, A J Docherty, J J Reynolds, G Murphy.   

Abstract

We report that monolayers of human fibroblasts stimulated with concanavalin A were able to activate 72 kDa progelatinase but not 95 kDa progelatinase. The activating capacity of fibroblasts appeared approx. 6 h after concanavalin A stimulation and was blocked by cycloheximide. The activation of 72 kDa progelatinase was readily inhibited by TIMP-2 but only poorly by TIMP-1. Plasma membranes isolated from the fibroblasts were capable of activating 72 kDa progelatinase. The cleavage products of the plasma membrane-mediated activation of 72 kDa progelatinase corresponded to those of organomercurial-induced self-cleavage. Only inhibitors of metalloproteinase self-cleavage inhibited the activating capacity of plasma membrane preparations, although the activating capacity was destroyed by trypsin and heat. As with the fibroblast monolayers, TIMP-2 was a potent inhibitor of the membrane-mediated activation whereas TIMP-1 was less so.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911847     DOI: 10.1016/0167-4838(91)90132-j

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  31 in total

1.  Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.

Authors:  Y Jo; J Yeon; H J Kim; S T Lee
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases.

Authors:  S J Atkinson; R V Ward; J J Reynolds; G Murphy
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

3.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.

Authors:  A H Baker; A B Zaltsman; S J George; A C Newby
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

Review 4.  Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling.

Authors:  V Everts; E van der Zee; L Creemers; W Beertsen
Journal:  Histochem J       Date:  1996-04

5.  Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Authors:  R Mazzieri; L Masiero; L Zanetta; S Monea; M Onisto; S Garbisa; P Mignatti
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

6.  TNF-alpha-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts.

Authors:  K Migita; K Eguchi; Y Kawabe; Y Ichinose; T Tsukada; T Aoyagi; H Nakamura; S Nagataki
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

Review 7.  The role of matrix metalloproteinases in cystic fibrosis lung disease.

Authors:  A Gaggar; A Hector; P E Bratcher; M A Mall; M Griese; D Hartl
Journal:  Eur Respir J       Date:  2011-01-13       Impact factor: 16.671

8.  MT-MMP expression and localisation in human lung and breast cancers.

Authors:  M Polette; B Nawrocki; C Gilles; H Sato; M Seiki; J M Tournier; P Birembaut
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

9.  Expression of activated gelatinase in human invasive breast carcinoma.

Authors:  P D Brown; R E Bloxidge; E Anderson; A Howell
Journal:  Clin Exp Metastasis       Date:  1993-03       Impact factor: 5.150

10.  Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts.

Authors:  R V Ward; S J Atkinson; J J Reynolds; G Murphy
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.